Allogeneic stem cell transplantation in patients with β-thalassemia: King faisal specialist hospital and research centre experience

Hemoglobin

Volumn 33, Issue SUPPL. 1, 2009, Pages

  Al Jefri, A ^a   Ayas, A ^a   Al Musa, A ^a   Al Mahr, M ^a   Al Saleh, M ^a   Rifai, S ^a   Sabbah, R ^a   Al Seraihy, A ^a   Al Ahmari, A ^a   Khairy, E ^a   Al Hassan, I ^a   El Solh, H ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Stem cell transplantation; Thalassaemia

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; THYMOCYTE ANTIBODY;

ADOLESCENT; AGE DISTRIBUTION; ALLOGENEIC STEM CELL TRANSPLANTATION; BETA THALASSEMIA; CHILD; CONFERENCE PAPER; DISEASE SEVERITY; DONOR; EVENT FREE SURVIVAL; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PATIENT SATISFACTION; PRESCHOOL CHILD; SCHOOL CHILD; TREATMENT OUTCOME; WHOLE BODY RADIATION;

BETA-THALASSEMIA; GRAFT REJECTION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; RETROSPECTIVE STUDIES; RISK FACTORS; SAUDI ARABIA; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 73949102234     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630260903351841     Document Type: Conference Paper

References (10)

1. Walter M, Thomas ED. Bone marrow transplantation for thalassemia. The USA experience. Am J Pediatr Hematol Oncol. 1994;16(1):11-17.
2. Lucarelli G, Galimberti M, Giardini C, et al. Bone marrow transplantation in thalassemia: the experience of Pesaro. Ann N Y Acad Sci. 1998;850:270-275. (Pubitemid 28369767)
3. Mentzer W, Cowan M. Bone marrow transplantation for beta-thalassemia: the University of California San Fransisco experience. J Pediatr Hematol Oncol. 2000;22(6):598-601.
4. Pawlowska AB, Blazar BR, Angelucci E, Baronciani D, Shu XO, Bostrom B. Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia. Bone Marrow Transplant. 1997;20(11):915-920.
5. Chandy M, Balasubramanian P, Ramachandran SV, et al. Randomized trial of two different conditioning regimens for bone marrow transplantation in thalassemia-the role of busulfan pharmacokinetics in determining outcome. Bone Marrow Transplant. 2005;36(10):839-845.
6. Casper J, Knauf W, Kiefer T, et al. Treosulfan and Fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood. 2004;103(2):725-731.
7. Manna M, Nesci S, Andreani M, Tonucci P, Lucarelli G. Influence of the conditioning regimens on the incidence of mixed chimerism in thalassemic transplanted patients. Bone Marrow Transplant. 1993;12(Suppl. 1):70-73.
8. Bernardo ME, Zecca M, Piras E, et al. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major. Br J Haematol. 2008; 143(4):548-551.
9. Erer B, Angelucci E, Lucarelli G, et al. Hepatitis C virus infection in thalassemia patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant. 1994;14(3):369-372.
10. Gaziev J, Sodani P, Lucarelli G, et al. Second hematopoietic SCT in patients with thalassemia recurrence following rejection of the first graft. Bone Marrow Transplant. 2008;42(6):397-404.